![Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) logo and Quadracel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) logo](resources/images/logos/pq_logo.png){kind=logo}
a DTaP = Diphtheria, tetanus, and acellular pertussis;
b IPV = Inactivated poliovirus; c Hib = Haemophilus influenzae type b.
Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to H influenzae type b. Pentacel vaccine is approved for use as a 4-dose series in children 6 weeks through 4 years of age (prior to fifth birthday).
Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a fourth or fifth dose in the inactivated poliovirus vaccination (IPV) series, in children who have received 4 doses of Pentacel vaccine and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed).
The only Hib-containing DTaP-IPV
combination vaccine with a
4-dose indication1
The same liquid DTaP-IPV component as
in Pentacel vaccine1,2
Age
Birth Birth |
1 Month 1 Mo. |
2 Months 2 Mos. |
4 Months 4 Mos. |
6 Months 6 Mos. |
12 Months 12 Mos. |
15 Months 15 Mos. |
18 Months 18 Mos. |
19-23 Months 19-23 Mos. |
2-3 Years 2-3 Yrs. |
4-6 Years 4-6 Yrs. |
|---|---|---|---|---|---|---|---|---|---|---|
| Hep B | Hep B | Hep B | ||||||||
| DTaP | DTaP | DTaP | DTaP | DTaP | ||||||
| IPV | IPV | IPV | IPV | |||||||
| Hib | Hib | Hib | Hib | Hib | ||||||
| RV | RV | RVe | ||||||||
| PCV | PCV | PCV | PCV | PCV | ||||||
| Influenza (yearly) | ||||||||||
| MMRf | MMR | MMR | ||||||||
| Varicella | Varicella | |||||||||
| Hep A (2-dose series) | Hep A (2-dose series) | |||||||||
| MenACWY | ||||||||||
| PPSV | ||||||||||
Birth Birth |
1 Month 1 Mo. |
2 Months 2 Mos. |
4 Months 4 Mos. |
6 Months 6 Mos. |
12 Months 12 Mos. |
15 Months 15 Mos. |
18 Months 18 Mos. |
19-23 Months 19-23 Mos. |
2-3 Years 2-3 Yrs. |
4-6 Years 4-6 Yrs. |
|---|---|---|---|---|---|---|---|---|---|---|
| Hep B | Hep B | Hep B | ||||||||
| Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | ||||||
|
|
 |
||||||||
| Hib | ||||||||||
| RV | RV | RVe | ||||||||
| PCV | PCV | PCV | PCV | PCV | ||||||
| Influenza (yearly) | ||||||||||
| MMRf | MMR | MMR | ||||||||
| Varicella | Varicella | |||||||||
| Hep A (2-dose series) | Hep A (2-dose series) | |||||||||
| MenACWY | ||||||||||
| PPSV | ||||||||||
Birth Birth |
1 Month 1 Mo. |
2 Months 2 Mos. |
4 Months 4 Mos. |
6 Months 6 Mos. |
12 Months 12 Mos. |
15 Months 15 Mos. |
18 Months 18 Mos. |
19-23 Months 19-23 Mos. |
2-3 Years 2-3 Yrs. |
4-6 Years 4-6 Yrs. |
|---|---|---|---|---|---|---|---|---|---|---|
| Hep B | Hep B | Hep B | ||||||||
| Dose 1 | Dose 2 | Dose 3 | Dose 4 | Dose 5 | ||||||
|
|
|
 |
||||||||
| Hib | ||||||||||
| RV | RV | RVe | ||||||||
| PCV | PCV | PCV | PCV | PCV | ||||||
| Influenza (yearly) | ||||||||||
| MMRf | MMR | MMR | ||||||||
| Varicella | Varicella | |||||||||
| Hep A (2-dose series) | Hep A (2-dose series) | |||||||||
| MenACWY | ||||||||||
| PPSV | ||||||||||
Pentacel + Quadracel vaccines allow you to use only 2 products across the entire childhood series.1-3
Given at 2, 4, 6, and 15-18 months, Pentacel vaccine, as a combination vaccine, may help increase timeliness of vaccination and patient compliance.6,7
In a pivotal trial among children 4-6 years of age, Quadracel vaccine induced antibody responses non-inferior to separately administered vaccines, DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) and IPOL® (Poliovirus Vaccine Inactivated) vaccines2
The most common local and systemic adverse reactions to Pentacel vaccine, which were comparable to those seen after DAPTACEL and IPOL, include erythema, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. The most common local and systemic adverse reactions to Quadracel vaccine, which were comparable to those seen after DAPTACEL and IPOL, include pain, erythema, and edema at the injection site; myalgia, malaise, and headache.1,2
By using Quadracel vaccine, a combination booster dose, you can complete the series and potentially reduce the number of injections needed and the number of vaccines in your refrigerator2,3
Using Pentacel and Quadracel vaccines together, you can have continuity of DTaP and IPV antigens across the 5-dose series1,2,4
Contraindications to vaccination with Pentacel or Quadracel vaccine include: a severe allergic reaction (eg, anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or
Contraindications to vaccination with Pentacel or Quadracel vaccine include: a severe allergic reaction (eg, anaphylaxis) to any ingredient of the vaccine, or following any other diphtheria toxoid-, tetanus toxoid-, pertussis antigen-containing vaccine, inactivated poliovirus vaccine, or Haemophilus influenzae type b vaccine (Pentacel vaccine only); encephalopathy within 7 days after a previous dose of a pertussis antigen-containing vaccine with no other identifiable cause; or a progressive neurologic disorder.
Carefully consider benefits and risks before administering Pentacel or Quadracel vaccine to persons with a history of: fever ≥105°F, hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures within 3 days after a previous pertussis antigen-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks following receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Pentacel or Quadracel vaccine or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.
For infants and children with a history of previous seizures, an antipyretic may be administered (in the dosage recommended in its prescribing information) at the time of vaccination with Pentacel vaccine and for the next 24 hours.
Apnea following intramuscular vaccination has been observed in some infants born prematurely.
The most common local and systemic adverse reactions to Pentacel vaccine include erythema, swelling, and tenderness at the injection site; fever, fussiness, and abnormal crying. The most common local and systemic adverse reactions to Quadracel vaccine include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.
Vaccination with Pentacel or Quadracel vaccine may not protect all individuals.
Please see the full Prescribing Information for Pentacel (49281-0510-05 and 49281-0511-05) or Quadracel vaccine.
CPT®g Code for Pentacel vaccine: 90698
CPT Code for Quadracel vaccine: 90696
g CPT (Current Procedural Terminology) is a registered trademark of the American Medical Association.
Pentacel vaccine is manufactured by Sanofi Pasteur Limited and Sanofi Pasteur SA and distributed by Sanofi Pasteur Inc.
Quadracel vaccine is manufactured by Sanofi Pasteur Limited and distributed by Sanofi Pasteur Inc.
Prescribing Information for Pentacel (49281-0510-05 and 49281-0511-05) and Quadracel Vaccines
